Prospects for molecular farming in the green alga Chlamydomonas

Protein-based therapeutics have enjoyed great success over the past decade. Unfortunately, this clinical success has come with a heavy price tag that is due to the inherently high costs of the capitalization and production of these complex molecules using current mammalian-based fermentation systems. Recent progress has been made in the production of recombinant proteins, including antibodies, in the eukaryotic unicellular green alga Chlamydomonas reinhardtii. C. reinhardtii offers an attractive alternative to traditional mammalian-based expression systems for several reasons, including its ability to provide stable plastid and nuclear transformants rapidly and its inherently low costs for capitalization and production.